Haemonetics (HAE) Q2 2026: Plasma Organic Growth Hits 19%, Margin Expansion Outpaces Portfolio Headwinds
Haemonetics delivered a standout Q2 with plasma organic growth at 19% and record margin expansion, even as reported revenue declined due to portfolio transitions. Strategic execution in plasma and blood management technologies offset interventional softness, and management raised guidance on both top-line and cash flow. Investors should watch the turnaround in interventional technologies and the sustainability of plasma momentum into FY27.
Summary
- Plasma Outperformance Drives Upward Revisions: Share gains and innovation in plasma collection led to raised full-year guidance.
- Margin Expansion Accelerates: All segments contributed to record operating margins as cost discipline and mix shift took hold.
- Interventional Technologies Remain a Rebuild Story: Turnaround efforts in vascular closure are showing early traction but remain a key watchpoint.
Performance Analysis
Haemonetics’ Q2 headline numbers mask a decisive shift in business quality. While reported revenue fell 5% due to the prior year’s $48 million portfolio transition, underlying organic growth (excluding the CSL transition) reached 9%. Plasma was the clear standout, posting 19% organic growth as share gains, innovation-driven pricing, and a return to high single-digit U.S. collection volumes converged. Hospital segment revenue grew 4% organically, propelled by blood management technologies (BMT) up 12%, while interventional technologies (IVT) lagged with a 5% decline, mainly from esophageal cooling softness.
Margins surged across the business, with adjusted gross margin reaching 60.5% and operating margin hitting a record 26.7%, up 250 basis points year-over-year. Segment-level margin expansion was broad-based: hospital (+370bps), plasma (+190bps), and blood center (+320bps). Operating cash flow more than doubled, and free cash flow conversion exceeded 80% year-to-date. The company raised full-year revenue, EPS, and free cash flow guidance, reflecting confidence in the sustainability of execution.
- Plasma Growth Reaccelerates: Share gains, innovation pricing, and volume recovery drove plasma organic growth to 19%.
- Hospital Margin Leadership: BMT strength and cost leverage made hospital the largest incremental margin contributor.
- Portfolio Rationalization Pays Off: Blood center segment benefited from the whole blood divestiture, lifting margins and focus.
Despite a drag from legacy product exits, Haemonetics’ core franchises are delivering outsized growth and profitability, setting a foundation for continued expansion as interventional technologies stabilize and new product launches scale.
Executive Commentary
"Our results reflect disciplined execution, delivering strong core product growth, record margin expansion, and solid earnings that convert to cash, while advancing our portfolio and company transformation to sustain this momentum well beyond our long-range plan."
Chris Simon, Chief Executive Officer
"Adjusted gross margin reached 60.5% in the second quarter and 60.6% year to date, up 380 and 460 basis points, respectively. The expansion was driven by the continued adoption of our persona technology, price initiatives across the portfolio, and favorable product mix, all of which are expected to continue to support margins in the second half."
James Durecka, Chief Financial Officer
Strategic Positioning
1. Plasma Franchise: Share Gain and Innovation-Driven Flywheel
Plasma, the company's largest growth driver, is benefiting from a powerful trifecta: share gains as more centers adopt Haemonetics’ devices, innovation-led pricing with premium products, and a recovery in collection volumes. Management’s confidence is rooted in both customer feedback and industry forecasts, with high single-digit U.S. collection growth seen as sustainable. The Nexus platform, apheresis-based plasma collection technology, is central to this momentum, enabling both customer share gains and margin expansion.
2. Blood Management Technologies: Durable Double-Digit Growth Engine
BMT continues to deliver consistent double-digit growth, driven by increased disposable utilization and the global rollout of the heparinase neutralization (HN) cartridge, which improves viscoelastic testing. Transfusion management also posted double-digit gains, adding breadth to the hospital segment’s performance. With a 70%+ share in viscoelastic testing and new launches in Europe and Japan, Haemonetics is well positioned for sustained growth in this underpenetrated category.
3. Interventional Technologies: Turnaround in Progress
IVT remains a drag on top-line growth, but management is executing a focused turnaround. Vascular closure products (Vascade, MVP, MVP XL) are seeing targeted commercial investments, new sales leadership, and field force realignment. Green shoots are emerging, with new account wins and competitive take-backs, but guidance remains conservative as the company works through competitive pressures and legacy product headwinds. The anticipated acquisition of Vivasure, large-bore closure device, is seen as a major FY27 catalyst.
4. Portfolio Rationalization and Capital Allocation
The divestiture of the whole blood franchise and exit from low-margin products have sharpened focus and improved margins, particularly in the blood center segment. Capital deployment is balanced between debt reduction, opportunistic share buybacks, and targeted innovation investments, with M&A on hold until IVT stabilizes. Management’s discipline is reflected in flat G&A and robust free cash flow conversion.
5. Margin Expansion as a Strategic Hallmark
Margin expansion is not a one-off event but a core strategic lever, with gains from price, mix, and productivity initiatives seen as durable. Software license fees and persona technology adoption provided incremental benefits, and management expects further leverage as volume scales in core franchises.
Key Considerations
Haemonetics’ quarter was defined by the interplay of growth, margin, and transformation, with the following considerations shaping its trajectory:
Key Considerations:
- Plasma Market Strength: Sustained end-market demand for immunoglobulin therapies and robust U.S. and European collection growth underpin long-term plasma upside.
- Execution in BMT and Transfusion Management: Consistent double-digit growth and global product launches reinforce Haemonetics’ leadership in hospital blood management.
- IVT Commercial Rebuild: Turnaround in vascular closure is underway, but visibility on timing and magnitude of recovery remains limited.
- Portfolio Rationalization Impact: Margin and focus gains from divestitures are now manifesting, especially in blood center results.
- Capital Allocation Discipline: Debt paydown and share buybacks are prioritized, with M&A limited to the Vivasure transaction pending IVT stabilization.
Risks
Key risks include the potential for renewed competitive pricing in vascular closure, slower-than-expected adoption of new products in international markets, and the risk that plasma collection volumes revert to historical cyclicality. Portfolio transitions are largely complete, but any delays in the IVT turnaround or regulatory setbacks (such as with Vivasure) could weigh on future growth and margin expansion.
Forward Outlook
For Q3 and the remainder of FY26, Haemonetics guided to:
- Full-year organic revenue growth (excluding CSL) of 7% to 10% (raised from 6% to 9%)
- Adjusted EPS of $4.80 to $5.00 (raised from prior guidance)
- Free cash flow of $170 million to $210 million (raised)
For full-year 2026, management expects:
- Adjusted operating margin of 26% to 27% (reaffirmed)
Drivers of guidance include continued plasma share gains, sustained BMT momentum, and disciplined expense management. Management remains conservative on interventional technologies, with little to no growth contribution assumed for the remainder of FY26.
- Plasma and BMT to drive the majority of growth and margin upside
- IVT recovery to be gradual, with FY27 as a more material inflection point
Takeaways
Haemonetics’ Q2 results highlight a business in transition, with core franchises delivering strong growth and margin expansion despite portfolio headwinds. The plasma segment’s outperformance is both structural and cyclical, while BMT continues to compound share in a market it helped create. IVT remains a key execution watchpoint, but early signs of stabilization are emerging.
- Plasma and BMT Outperformance: These segments are now the primary value creation levers, with innovation and share gains sustaining growth and profitability.
- IVT Turnaround Trajectory: Commercial investments and new leadership are stabilizing vascular closure, but investors should expect a gradual recovery path.
- Margin and Cash Flow Durability: Operating leverage and disciplined allocation underpin confidence in multi-year margin expansion and cash generation.
Conclusion
Haemonetics’ Q2 2026 results demonstrate the power of focused execution and portfolio transformation, with plasma and blood management technologies driving record margins and cash flow. While interventional technologies remain a work in progress, the company’s core franchises are well positioned for continued growth and value creation into FY27 and beyond.
Industry Read-Through
Haemonetics’ plasma performance is a leading indicator for the broader plasma therapeutics and blood management sector, signaling renewed demand for immunoglobulin therapies and a return to volume growth in U.S. and European collections. Margin expansion via portfolio rationalization and innovation-led pricing is a playbook for medtech peers facing similar legacy drag. The IVT turnaround underscores the importance of targeted commercial investment and clinical differentiation in competitive device markets. Overall, Haemonetics’ disciplined capital allocation and focus on core growth franchises offer a template for sustainable value creation in healthcare technology.